NRX Pharmaceuticals (NRXP) Stock Price

NRX Pharmaceuticals Price

NASDAQ·CLOSED
2.38
​
Market closed

The consensus 12-month price target for NRX Pharmaceuticals is 2.04 USD, about 14.3% below where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

NRX Pharmaceuticals stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NRX Pharmaceuticals business model & stock analysis

NRX Pharmaceuticals Inc, based in Wilmington, Delaware, is a clinical-stage pharmaceutical company focused on developing therapeutics for central nervous system disorders. The company is engaged in the development of NRX-101, an oral combination therapy targeting NMDA receptors for bipolar depression and suicidal ideation, currently in Phase III trials under FDA Special Protocol Agreement. It also operates a Phase IIb trial for sub-acute suicidality and develops aviptadil acetate (ZYESAMI) for respiratory failure in COVID-19 patients, alongside NRX-100, a generic anesthetic based on racemic ketamine.

Frequently asked questions about NRX Pharmaceuticals

Analysts currently set an average price target of 3.23 USD for the NRX Pharmaceuticals stock (median: 2.04 USD), implying +36.9 % versus the latest price. The consensus is based on 9 analyst ratings.

11 analysts currently rate the NRX Pharmaceuticals stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect NRX Pharmaceuticals to generate revenue of 5.51 M USD and earnings per share of -0.77 USD.

Converted at the current exchange rate, the NRX Pharmaceuticals share trades at 2.14 EUR (2.38 USD).

The NRX Pharmaceuticals share (NRXP) is listed on 4 stock exchanges, including: NASDAQ (NRXP), Frankfurt (B1QB.F), München (B1QB.MU), Düsseldorf (B1QB.DU).

The expected revenue of NRX Pharmaceuticals is 5.51 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of NRX Pharmaceuticals is -24.43 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of NRX Pharmaceuticals is currently -3.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the NRX Pharmaceuticals stock.

The price-to-sales ratio (P/S) of NRX Pharmaceuticals is currently 13.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the NRX Pharmaceuticals stock.

The Eulerpool Quality Score for NRX Pharmaceuticals is 4/10.

The ISIN of NRX Pharmaceuticals is US6294442099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of NRX Pharmaceuticals is A3CQ3Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of NRX Pharmaceuticals is NRXP. The ticker symbol is used to trade NRX Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
2.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
612,500.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 20, 2017
ISIN
US6294442099
Cusip
629444100
Market capitalization
66.88 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-3.09
P/Ee 2027
-6.56
P/Ee 2028
15.87
P/Ee 2029
3.35
P/Ee 2030
2.09
P/Se
13.71
EV/EBIT
—
P/B Ratio
9.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
187.00 %
Last updated Nov 12, 2026, 3:41 AM

NRX Pharmaceuticals Peer Group

NRX Pharmaceuticals Ticker

DÜSSELDORF · B1QB.DUFRANKFURT · B1QB.FMUNICH · B1QB.MUNASDAQ · NRXP